Login
Login     |     Register     |     Recover Username/Password

Boris Peaker

Oppenheimer & Co. Inc.

Boris Peaker, Ph.D., is Executive Director and Senior Analyst with Oppenheimer & Co. Inc., covering the biotechnology sector. Prior to joining Oppenheimer & Co. Inc., he was an Analyst at Rodman & Renshaw, covering small and midcap biotech companies across multiple therapeutic areas. Prior to Rodman & Renshaw, Dr. Peaker covered mid- and large-cap U.S.-based biopharmaceutical and biotechnology companies at Cowen Group. He began his career as a Consultant at Keelin Reeds Partners in Palo Alto, California, working exclusively with biotechnology and pharmaceutical companies on asset valuation, R&D portfolio management, M&A strategy, and royalty and equity financing. He holds a Ph.D. in biophysics from Stanford University and a dual B.S. in physics and chemistry from SUNY Stony Brook.

Strong Outlook for Orphan and Oncology Treatments
April 24, 2014 - Pharmaceuticals

Oncology and Orphan Drugs Retain Pricing Power
September 13, 2013 - Pharmaceuticals

Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs
April 26, 2013 - Pharmaceuticals

Emerging-Growth Opportunities in Oncology Biotech
September 17, 2012 - Pharmaceuticals

Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now